← Back to Home

How Can Recurrence Be Reduced After Liver Cancer Resection? Personalized DNA Vaccine Enters Randomized Phase 2 Trial

Geneos will make vaccines based on mutations in each patient’s tumor and compare them with active surveillance after surgery. The study, expected to enroll 90 patients, will test whether the immune system’s ability to recognize cancer cells can translate into a longer time without recurrence.

By SURL BioNews

After surgical resection of liver cancer, the absence of a tumor on imaging does not mean the risk of recurrence has disappeared. Providing protection during this period without visible disease is an important challenge in postoperative treatment. Geneos Therapeutics announced on October 21 that it had initiated IMPACT31, a randomized Phase 2 clinical trial that will use mutations in each patient’s own tumor to test whether personalized DNA immunotherapy can reduce the risk of hepatocellular carcinoma recurrence.

According to the company’s announcement and the same press release published by BioSpace, the study is expected to enroll 90 patients in the United States and the Asia-Pacific region who have undergone resection with curative intent but are at high risk of recurrence. Mirrored trial registry data further specify that participants must show no evidence of disease on magnetic resonance imaging approximately 28 days after surgery and be able to provide tumor tissue to produce a personalized vaccine. This focuses the study on adjuvant treatment after surgery, rather than shrinking existing tumors.

At the core of the experimental therapy is GNOS-PV02. Researchers first analyze tumor sequences to identify “neoantigens” arising from mutations that the immune system can recognize, then insert the corresponding coding sequences into DNA plasmids. The idea is to teach immune cells to recognize the characteristics of the patient’s tumor and target cancer cells that may remain. Whether this can provide sufficient protection to prevent recurrence is the question this trial aims to answer.

According to the registry data, the treatment group will also receive INO-9012, a plasmid encoding interleukin-12, as an additional immune-stimulating component. Administration involves intradermal injection followed by electroporation to help the DNA enter cells. The control group will undergo active surveillance. The study uses an open-label design, meaning patients and medical teams will know the treatment assignments, so the potential effects of that knowledge must also be considered when assessing the results.

The primary endpoint is recurrence-free survival over up to five years, counting local or distant recurrence, new primary hepatocellular carcinoma, and death from any cause. The study will also track overall survival and adverse events during treatment. These measures move the question beyond whether an immune response can be triggered to whether patients actually experience delayed recurrence and how much treatment burden they bear in return.

The company cites earlier studies in advanced liver cancer as the basis for development. However, advanced disease and the postoperative setting without visible disease are different clinical situations, and equivalent effects cannot be assumed. This announcement did not provide efficacy or safety results from IMPACT31. The launch of the randomized controlled study marks a more rigorous stage of testing for this personalized therapy; actual recurrence and survival data are still needed to support its use as a routine postoperative option.

References

  1. PR Newswire
  2. ICH GCP clinical-trial registry mirror
  3. BioSpace (Geneos Therapeutics press release)